Supriya Lifescience, one of India’s leading speciality active pharmaceutical ingredients (API) manufacturing company and CDMO signs an agreement with Kalinga Institute of Technology for further development of GelHeal, a protein-based crosslinked Hydrogel. The gel-based cream is mapped out and designed taking into account the In-Situ scaffolding for mechanical support into the deep wounds and scar-free skin regeneration.
The gel-based cream may prove to be prolific in easing and healing not only third-degree wounds, cuts, bite/ballistic wounds but also diabetic foot ulcers, pressure ulcers, venous leg ulcers and surgery wounds.
This radical shift in dermatology and skin grafting would also now cater to scar-free skin, not mandating repetitive hospitalization through the topical formulation for skin regeneration gel, thus proving cost cost-effective and less time-consuming medical solution for many.
With such functionalities, GelHeal also fabricates mechanisms for preventing infection, avoiding over-drying while accommodating a moist environment, mechanical support for strain-less wound closure and Scaffold Support Skin Regeneration Support thus resulting in scar-free skin.
Dr. Satish Wagh, Founder and Chairman, Supriya Lifescience Ltd says, “As we have already demarcated positive change by recently signing an agreement to develop Quickblue which is the oral cancer detection kit in collaboration with Kalinga Institute of Industrial Technology, we are looking forward in aiding more innovative products like GelHeal, the simplest and cheapest wound healing gel”.
Dr. Satish Wagh further said, “Supriya Lifescience has established itself as a CDMO player over decades, Supriya Lifescience is putting a step forward into diversification of our business by banking on our world-class CDMO capabilities and offering niche products for healthcare needs. We believe more and more of such products will establish Supriya Lifescience Ltd as an integrated healthcare provider.”